Non-Hodgkin lymphoma (NHL) represents the fourth malignant disease in children and adolescents and comprises a heterogeneous group of diseases with high biological diversity.
Unlike adults, most pediatric NHLs show an aggressive behavior and despite having achieved a very high survival rate in recent decades (80-90%), the outcome is poor in case of relapse.
The current management in our country is based on regimens of polychemotherapy and targeted therapies, administered in highly specialized centers in pediatric oncology and always in the context of international guidelines or clinical trials.
Some patients with predisposing syndromes (immunodeficiencies, alterations in DNA repair mechanisms, etc.) have a higher probability of developing some type of NHL. Individualized diagnosis and therapeutic management in these cases remains a challenge.
In recent years, the pediatric NHL group belonging to the Spanish Society of Pediatric Hematology and Oncology (SEHOP) has made possible to standardize the diagnostic and therapeutic approach to NHL in children and adolescents at a national level.
The NHL-SEHOP 2018 registry, through the centralization of clinical data and biological samples for centralized diagnostic review, has improved the knowledge of the clinical and biological characteristics of NHL in our country.
This project provides real-time diagnostic and therapeutic advice to collaborating centers, and promotes research in the field, allowing the application of advanced biological studies, and the development of clinical and translational research projects at the national and international level.
The group, through its biological research team, has identified genetic alterations potentially involved in the development of pediatric lymphomas, reflecting the biological differences between pediatric and adult NHL. In addition, the reference biological team participates in the implementation of essential diagnostic techniques to allow access to patients into international clinical trials.
The work of the group is focused on facilitating an adequate diagnosis of pediatric NHL and promoting clinical and translational research to establish new more effective therapeutic strategies, particularly in patients with relapse, and with a lower toxicity in patients with good prognosis factors.
The NHL group actively participates within the European Inter-Group for Childhood Non-Hodgkin Lymphoma (EICNHL) to develop future diagnostic and therapeutic strategies for our NHL patients.
The research of this group can be carried out thanks to the funders.
Asociación Española Contra el Cáncer
Instituto de Salud Carlos III
Sociedad Española de Hematología y Oncología Pediátricas
International BFM Study Group